Cash rich start-ups are filing scores of patent claims on hallucinogens like magic mushrooms. Researchers and patient advocates worry high prices will make the therapies unaffordable. George Goldsmith, co-founder and executive chairman of Compass Pathways in London. Credit… Tom Jamieson for The New York Times Send any friend a story As a subscriber, you have 10 gift articles to give each month.
Read More from the Global Wellness News ™